Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

J. Lynch, Thomas; Bondarenko, Igor; Luft, Alexander; Serwatowski, Piotr; Barlesi, Fabrice; Chacko, Raju; Sebastian, Martin; Neal, Joel; Lu, Haolan; Cuillerot, Jean-Marie; Reck, Martin

doi:10.1200/jco.2011.38.4032

Public

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Shared by NobleBlocks on Jun 10, 2012 • 12:00 AM UTC

Authors:

Thomas J. Lynch

Igor Bondarenko

Alexander Luft

Abstract

Purpose Ipilimumab, which is an anti–cytotoxic T-cell lymphocyte-4 monoclonal antibody, showed a survival benefit in melanoma with adverse events (AEs) managed by protocol-defined guidelines. A phase II study in lung cancer assessed the activity of ipilimumab plus paclitaxel and carboplatin. Patient...

Discussions